XML 33 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements Of Cash Flows - USD ($)
 12 Months Ended
Jan. 26, 2025
Jan. 28, 2024
Jan. 29, 2023
Cash flows from operating activities:      
Net income $ (161,896,000) $ (1,092,029,000) $ 61,372,000
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:      
Depreciation and amortization 43,499,000 77,968,000 32,151,000
Amortization of right-of-use assets 5,872,000 6,484,000 4,742,000
Right-of-use asset impairment 0 3,884,000 0
Investment impairments and credit loss reserves, net 1,109,000 3,929,000 1,156,000
Impairment of goodwill 7,490,000 755,621,000 0
Intangible impairment 0 131,385,000 0
Accretion of deferred financing costs and debt discount 8,274,000 7,320,000 1,421,000
Write-off of deferred financing cost and debt discount 13,246,000 4,446,000 0
Loss on extinguishment of debt 143,467,000 0 0
Interest rate swap termination (3,579,000) 0 0
Deferred income taxes (21,672,000) 40,636,000 (15,256,000)
Share-based compensation 68,036,000 40,170,000 39,248,000
Loss (gain) on disposition of business operations and assets 262,000 8,000 (18,260,000)
Equity in net (gains) losses of equity method investments 547,000 (45,000) (249,000)
Gain from sale of investments (277,000) 0 0
Corporate owned life insurance, net 3,411,000 4,746,000 810,000
Amortization of inventory step-up 0 3,314,000 0
Changes in assets and liabilities:      
Accounts receivable, net (28,348,000) 27,443,000 2,445,000
Inventories (18,666,000) 57,308,000 (3,752,000)
Other assets 3,137,000 1,817,000 6,302,000
Accounts payable 14,682,000 (44,346,000) (3,697,000)
Accrued liabilities (4,623,000) (118,517,000) 18,921,000
Other liabilities (15,984,000) (5,462,000) (643,000)
Net cash provided by (used in) operating activities 57,987,000 (93,920,000) 126,711,000
Cash flows from investing activities:      
Proceeds from sales of property, plant and equipment 97,000 410,000 38,000
Purchase of property, plant and equipment (7,861,000) (29,185,000) (28,323,000)
Proceeds from sale of investments 2,650,000 0 2,275,000
Purchase of investments (434,000) (930,000) (6,748,000)
Purchase of intangibles (6,341,000) (1,915,000) 0
Proceeds from sale of business, net of cash disposed 0 0 26,193,000
Acquisition, net of cash acquired 0 0 (1,240,757,000)
Proceeds from corporate-owned life insurance 4,802,000 8,923,000 5,065,000
Premiums paid for corporate-owned life insurance (4,800,000) 0 (5,065,000)
Net cash used in investing activities (11,887,000) (22,697,000) (1,247,322,000)
Cash flows from financing activities:      
Proceeds from revolving line of credit 68,250,000 70,000,000 10,000,000
Payments of revolving line of credit (283,250,000) (5,000,000) (33,000,000)
Proceeds from term loans 0 0 895,000,000
Payments of term loans (441,413,000) (272,375,000) 0
Proceeds from convertible senior notes 0 250,000,000 319,500,000
Proceeds from sale of warrants 0 0 42,909,000
Purchase of convertible note hedge 0 0 (72,559,000)
Proceeds from issuance of common stock, net of issuance costs 640,675,000 0 0
Proceeds from interest rate swap termination 4,776,000 0 0
Deferred financing costs (824,000) (25,361,000) (21,760,000)
Payments for employee share-based compensation payroll taxes (14,025,000) (6,714,000) (14,190,000)
Proceeds from exercise of stock options 4,335,000 0 620,000
Repurchase of common stock 0 0 (50,000,000)
Distributions to noncontrolling interest (184,000) 0 0
Net cash (used in) provided by financing activities (21,660,000) 10,550,000 1,076,520,000
Effect of foreign exchange rate changes on cash and cash equivalents (1,282,000) (858,000) 0
Net increase (decrease) in cash and cash equivalents 23,158,000 (106,925,000) (44,091,000)
Cash and cash equivalents at beginning of period 128,585,000 235,510,000 279,601,000
Cash and cash equivalents at end of period 151,743,000 128,585,000 235,510,000
Supplemental disclosure of cash flow information      
Interest paid 72,454,000 83,583,000 11,745,000
Income taxes paid 7,979,000 19,758,000 10,364,000
Non-cash items      
Capital expenditures in accounts payable 183,000 860,000 9,390,000
Accrued deferred financing costs 0 828,000 2,767,000
Accrued purchase of intangibles 1,600,000 0 0
Debt extinguished in exchange for common stock 188,050,000 0 0
Conversion of note into equity $ 0 $ 1,271,000 $ 0